Friday, August 16, 2019 1:19:37 PM
Nice preclinical work similar to what the other sigma 1 failures had. I've given links several times to both pre clincal and the failed P2 studies. M1 study abandoned for cognition failure already as well.
Pridopidine study. Sounds good pre clinic. https://www.ncbi.nlm.nih.gov/pubmed/30756361
Not so good in the clinic. From January article.
https://huntingtonsdiseasenews.com/2019/01/03/huntexil-fails-to-improve-motor-function-of-huntingtons-patients-in-phase-2-trial/
Toyama's Sigma1 drug, T-817MA AD.
Looked great pre clinical.
https://www.fujifilmholdings.com/en/news/2014/0609_01_01.html
Failed in the clinic.
https://www.genengnews.com/news/fujifilms-alzheimers-candidate-fails-phase-ii-trial/
M1 AD trial last year. Abandoned.
https://www.sciencedirect.com/science/article/pii/S235287371830012X
Plenty of things work well in preclinical studies and plenty of drugs claim autophagy or degrees of homeostasis. Even things other than drugs claim to promote autophagy including fasting.
What I haven't heard is a reason that restoring normal endogenous brain enzyme levels, therefore regrowing the synpatic network would NOT result in successful AD trials. This is no longer preclinical in nature or a hypothesis paper. Its in human trials.
https://neurotrope.com/wp-content/uploads/2018/12/JAD180759.pdf
Pridopidine study. Sounds good pre clinic. https://www.ncbi.nlm.nih.gov/pubmed/30756361
Not so good in the clinic. From January article.
https://huntingtonsdiseasenews.com/2019/01/03/huntexil-fails-to-improve-motor-function-of-huntingtons-patients-in-phase-2-trial/
Toyama's Sigma1 drug, T-817MA AD.
Looked great pre clinical.
https://www.fujifilmholdings.com/en/news/2014/0609_01_01.html
Failed in the clinic.
https://www.genengnews.com/news/fujifilms-alzheimers-candidate-fails-phase-ii-trial/
M1 AD trial last year. Abandoned.
https://www.sciencedirect.com/science/article/pii/S235287371830012X
Plenty of things work well in preclinical studies and plenty of drugs claim autophagy or degrees of homeostasis. Even things other than drugs claim to promote autophagy including fasting.
What I haven't heard is a reason that restoring normal endogenous brain enzyme levels, therefore regrowing the synpatic network would NOT result in successful AD trials. This is no longer preclinical in nature or a hypothesis paper. Its in human trials.
https://neurotrope.com/wp-content/uploads/2018/12/JAD180759.pdf
Recent TAOX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:01:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:01:11 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 09:21:40 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/02/2026 09:32:45 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/02/2026 09:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:23:07 PM
- TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation • PR Newswire (US) • 11/18/2025 02:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/12/2025 09:10:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/07/2025 09:41:16 PM
- TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds • PR Newswire (US) • 11/04/2025 02:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/24/2025 08:12:47 PM
- TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency • PR Newswire (US) • 10/20/2025 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/17/2025 09:13:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 10:12:21 AM
- TAO Synergies Announces $11 Million Private Placement • PR Newswire (US) • 10/13/2025 09:09:00 PM
- TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO) • PR Newswire (US) • 09/22/2025 01:15:00 PM
- TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event • PR Newswire (US) • 09/08/2025 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2025 09:00:44 PM
- TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy • PR Newswire (US) • 08/26/2025 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2025 08:51:57 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/14/2025 08:50:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 08:19:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 09:17:38 PM
